HealthQuill FDA
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
Drugs Health Pharma

Biogen’s ALS drug gets European Commission’s marketing nod

The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.

Read More
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people with type 1 diabetes, with seven members voting for and four against.
Drugs Health Pharma

FDA panel rejects Novo Nordisk’s weekly jab to treat type 1 diabetes

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.

Read More
The US Food and Drug Administration has cleared Amgen’s drug to treat adult patients in the extensive stages of small cell lung cancer (ES-SCLC) with disease progression on or after chemotherapy.
Drugs Health Pharma

USFDA gives nod to Amgen’s therapy for treating small cell lung cancer 

HQ Team May 17, 2024: The US Food and Drug Administration has cleared Amgen’s drug to treat adult patients in the extensive stages.

Read More
A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer, according to a statement posted by a non-profit group on its website quoting a company statement.
Drugs Health Pharma

Boy dies during Pfizer’s clinical trial probing rare genetic disease

HQ Team May 8, 2024: A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer,.

Read More
Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the USFDA has given the green light to the company’s Anktiva treatment.
Drugs Health Pharma

USFDA grants approval for ImmunityBio’s bladder cancer drug

HQ Team April 23, 2024: Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the.

Read More
A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less effective old generic antibiotics — even though the US regulator has cleared seven next-generation antibiotics to deal with the germs.
Drugs Health Pharma

US doctors still prescribe old generic antibiotics, cost main factor

HQ Team April 20, 2024: A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less.

Read More
Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.
Drugs Medical Pharma

FDA’s accelerated approval of cancer drugs is hasty and doubtful, says new report

HQ Team April 10, 2024:  A new study has found that cancer drugs that got accelerated approval under the US Federal Drug Approval.

Read More
Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the marketing authorisations for its amyotrophic lateral sclerosis (ALS) therapy after the drug failed in a last-stage trial.
Drugs Health Pharma

Amylyx Pharma pulls out ALS therapy drug from US, Canada

HQ Team April 4, 2024: Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the.

Read More
The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and skin infections in adults and community-acquired bacterial pneumonia in patients three months to 18 years, and adults. 
Drugs Health Pharma

Swiss-based Basilea Pharmaceutical’s antimicrobial drug gets FDA nod 

HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.

Read More
The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to “unreasonable and substantial risk” of illness or injury.
Drugs Medical Pharma

FDA attempts a second time to ban electrical stimulation devices

HQ Team March 26, 2024: The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to “unreasonable and.

Read More
X